Zydus Lifesciences Limited (NSE:ZYDUSLIFE)

Zydus Lifesciences Balance Sheet

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Cash & Equivalents	-	8,268	4,130	5,731	11,069	8,883
Short-Term Investments	-	42,703	6,875	-	5,134	-
Trading Asset Securities	-	5,401	2,525	6,193	23,532	1,989
Cash & Short-Term Investments	56,372	56,372	13,530	11,924	39,735	10,872
Cash Growth	315.23%	316.64%	13.47%	-69.99%	265.48%	-12.77%
Accounts Receivable	-	40,247	52,202	44,168	33,403	31,273
Other Receivables	-	4,828	3,551	2,181	1,991	2,832
Receivables	-	45,846	55,768	46,353	35,394	34,105
Inventory	-	39,440	34,419	34,133	37,194	32,362
Prepaid Expenses	-	1,144	1,021	1,016	721	908
Other Current Assets	-	27,659	9,460	6,656	7,908	8,913
Total Current Assets	-	170,461	114,198	100,082	120,952	87,160
Property, Plant & Equipment	-	73,599	69,148	68,267	64,226	63,332
Long-Term Investments	-	15,570	9,696	11,779	9,348	6,312
Goodwill	-	52,421	52,660	48,044	53,646	53,465
Other Intangible Assets	-	32,236	26,110	10,905	11,272	12,363
Long-Term Deferred Tax Assets	-	23,438	16,442	12,624	10,958	10,744
Other Long-Term Assets	-	4,292	4,554	5,843	7,552	5,471
Total Assets	-	372,017	292,808	257,564	277,954	238,847
Accounts Payable	-	23,058	21,267	21,250	21,378	22,059
Accrued Expenses	-	20,010	15,385	15,454	13,118	11,123
Short-Term Debt	-	31,743	7,863	10,812	33,142	30,785
Current Portion of Long-Term Debt	-	-	-	822	5,198	9,031
Current Portion of Leases	-	116	105	119	88	90
Current Income Taxes Payable	-	6,157	3,720	1,568	418	884
Other Current Liabilities	-	9,332	5,079	5,282	5,052	4,641
Total Current Liabilities	-	90,416	53,419	55,307	78,394	78,613
Long-Term Debt	-	-	-	-	3,621	6,095
Long-Term Leases	-	321	251	198	161	151
Long-Term Unearned Revenue	-	9	18	295	287	227
Long-Term Deferred Tax Liabilities	-	5,126	4,465	1,944	1,538	1,197
Other Long-Term Liabilities	-	8,722	10,542	219	165	173
Total Liabilities	-	108,433	71,792	60,681	87,416	89,551
Common Stock	-	1,006	1,006	1,012	1,024	1,024
Retained Earnings	-	247,988	206,062	181,163	172,855	131,739
Comprehensive Income & Other	-	-9,463	-8,773	-7,017	-3,883	-2,840
Total Common Equity	239,531	239,531	198,295	175,158	169,996	129,923
Minority Interest	-	24,053	22,721	21,725	20,542	19,373
Shareholders' Equity	263,584	263,584	221,016	196,883	190,538	149,296
Total Liabilities & Equity	-	372,017	292,808	257,564	277,954	238,847
Total Debt	32,180	32,180	8,219	11,951	42,210	46,152
Net Cash (Debt)	24,192	24,192	5,311	-27	-2,475	-35,280
Net Cash Growth	351.60%	355.51%	-	-	-	-
Net Cash Per Share	24.04	24.04	5.25	-0.03	-2.42	-34.46
Filing Date Shares Outstanding	1,006	1,006	1,006	1,012	1,024	1,024
Total Common Shares Outstanding	1,006	1,006	1,006	1,012	1,024	1,024
Working Capital	-	80,045	60,779	44,775	42,558	8,547
Book Value Per Share	238.05	238.05	197.07	173.05	166.05	126.91
Tangible Book Value	154,874	154,874	119,525	116,209	105,078	64,095
Tangible Book Value Per Share	153.91	153.91	118.78	114.81	102.64	62.61
Land	-	6,424	6,170	6,258	5,727	5,701
Buildings	-	23,733	21,906	20,748	19,688	20,454
Machinery	-	86,460	80,775	74,985	71,260	65,598
Construction In Progress	-	13,179	11,115	11,302	6,610	7,832

Updated Feb 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.